ABSTRACT
Cutaneous melanoma remains a major health issue and still an important challenge for research. Thus, omics complex evaluation can provide a more specific molecular classification for this heterogeneous disease. Complex omics analysis based on genomic and proteomic microarrays can identify disease markers that prognosticate disease evolution or can monitor therapies efficacy. Among the technologies that gained momentum in the last years, array-based comparative genomic hybridization offered the possibility to analyze chromosomal numerical aberrations within cutaneous melanomas providing important support for molecular classification of melanoma tumors. This technology can identify new chromosomal alterations and discover new deregulated melanoma genes that can be further used as therapy targets. Integrating genetic profiling with clinical and pathological parameters would lead to seminal improvements in diagnosis, prognosis, and therapy.
Acknowledgment
This article is part of the Ph.D. thesis of Ph.D. student Carmen Dumitru.
Funding
Authors were partially supported through grants PN - II - PCCA - 2013 - 4 – 1407 (acronym MELTAG, grant no. 190/2014) and COST Action 16120/2017 EPITRAN.